<DOC>
	<DOC>NCT02975297</DOC>
	<brief_summary>The purpose of this study is to identify a potential new treatment for smoking cessation.</brief_summary>
	<brief_title>Exenatide Once Weekly for Smoking Cessation</brief_title>
	<detailed_description />
	<mesh_term>Nicotine</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Be Englishspeaking volunteers who desire to quit smoking and are willing to make a quit attempt during the course of the study; Have smoked ≥10 cigarettes a day for at least one year and provide a breath CO ≥10 ppm; Have a negative pregnancy test, if female of childbearing potential; Have HbA1C levels between 5.7 and 6.4% or BMI of or greater than 25 kg/square meters Not currently using any therapy for glycemic control (either injectable [i.e. insulin] or oral agents); Have vital signs as follows: resting pulse between 50 and 95 bpm, BP between 90150 mmHg systolic and 4595 mmHg diastolic; Have hematology and chemistry laboratory tests that are within reference limits (within 10% above or below), with the following exception: pancreatic tests (lipase and amylase) must be within normal limits; Have a medical history and brief physical examination demonstrating no clinically significant contraindications for study participation, in the judgment of the principal investigator. Meet criteria for the following psychiatric and/or substance use disorders as assessed by the MINI: items C (current manic or hypomanic episode only), I (alcohol abuse Alcohol Addendumpast 3 months only; current alcohol dependence), J (substance abuse Substance Abuse Addendum past 3 months only; current substance dependence), K (current psychotic disorder or current mood disorder with psychotic features). Individuals who meet criteria for nonexclusionary psychiatric disorders that are considered clinically unstable and/or unsuitable to participate as determined by the Principal Investigator and/or Study Physician. Individuals rated as moderate (916) to high (17 or greater) on suicidality as assessed by Module B of the MINI. Have personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2; Have type 1 diabetes mellitus; Have severe cardiovascular disease (history of myocardial infarction, lifethreatening arrhythmia, or worsening angina pectoris); Have active temporomandibular joint disease; Have severe gastrointestinal disease (i.e. severe gastroparesis); Have previous history of pancreatitis or are at risk for pancreatitis; Have CrCl&lt;30; Have any previous medically adverse reaction to study medications, nicotine, or menthol; Be pregnant or lactating or unwilling to provide a negative pregnancy test before study entry; Not using a reliable form of contraception (e.g., abstinence, birth control pills, intrauterine device, condoms, or spermicide); Have any illness which in the opinion of the primary investigator would preclude safe and/or successful completion of the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>smoking</keyword>
	<keyword>pre-diabetes</keyword>
	<keyword>overweight</keyword>
	<keyword>exenatide</keyword>
	<keyword>GLP-1 agonists</keyword>
</DOC>